Cellyan Biotechnology Co., Ltd

Cellyan Biotechnology Co., Ltd announced it received an additional 180-day grace period from Nasdaq to regain compliance with the minimum $1.00 closing bid price requirement. The company was initially notified of non-compliance on January 12, 2026, with an original deadline of July 13, 2026. The new extension grants the company until January 11, 2027, to meet the requirement by maintaining a bid price of at least $1.00 for ten consecutive business days. Cellyan Biotechnology plans to coordinate feasible solutions, including a potential reverse share split, to restore listing compliance.

Cellyan Biotechnology Co., Ltd received a notification from Nasdaq's Listing Qualifications Department, granting an additional 180-day period until January 11, 2027, to regain compliance with the minimum $1.00 closing bid price requirement. To comply, the company must maintain a closing bid price of at least $1.00 for ten consecutive business days. Cellyan Biotechnology plans to implement feasible solutions, including a potential reverse share split, to restore its Nasdaq listing, though there is no assurance of success. The company's shares will continue to trade uninterrupted during this period.